Kidney Cancer Study Puts Circulating Tumor DNA Assay to Test
The study will examine whether Natera’s circulating tumor DNA assay can distinguish between recurring and nonrecurring cases of kidney cancer.
Read MorePosted by Steve Halasey | Sep 28, 2018 | Research |
The study will examine whether Natera’s circulating tumor DNA assay can distinguish between recurring and nonrecurring cases of kidney cancer.
Read MorePosted by Steve Halasey | Sep 24, 2018 | Molecular Diagnostics, Research |
Study data support use of the company’s ARM-D kits as comprehensive screening tools for β-lactamase-based resistance.
Read MorePosted by Steve Halasey | Sep 24, 2018 | Prenatal Testing, Research |
Statisticians used data from more than a million Panorama tests to devise an algorithm that computes a fetal fraction-based risk score for pregnancy.
Read MorePosted by Steve Halasey | Sep 24, 2018 | Software |
The powerful, flexible, and easy-to-use analysis solution gets the most out of NGS data.
Read MorePosted by Steve Halasey | Sep 17, 2018 | Fertility Testing, Research, Womens Health |
Natera’s genetic test evaluates the number of chromosomes in embryos to detect extra or missing chromosomes, and screens for inherited genetic disorders.
Read More